Related Experiment Video

Updated: Jun 30, 2026

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

15.1K

Successful Control of Langer hans Cell Sarcoma in a Super-Aged Patient Using Intensity-Modulated Radiotherapy

Hiromu Okuguchi1, Taku Fujimura1, Manami Takahashi-Watanabe1

  • 1Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan.

The Journal of Dermatology
|March 17, 2026
PubMed
Abstract

No abstract available in PubMed .

Keywords:
IMRTLangerhans cell sarcomalocal invasiontreatment

More Related Videos

An Immunocompetent Murine Model for Laser Interstitial Thermal Therapy of Glioblastoma
09:10

An Immunocompetent Murine Model for Laser Interstitial Thermal Therapy of Glioblastoma

Published on: November 15, 2024

1.0K

Related Experiment Videos

Last Updated: Jun 30, 2026

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

15.1K
An Immunocompetent Murine Model for Laser Interstitial Thermal Therapy of Glioblastoma
09:10

An Immunocompetent Murine Model for Laser Interstitial Thermal Therapy of Glioblastoma

Published on: November 15, 2024

1.0K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Articles linked to this work by shared authors, journal, and citation graph.

Cutaneous Squamous Cell Carcinoma Arising From Hidradenitis Suppurativa and Epidermal Cyst: Clinical Characteristics, Baseline Neutrophil-To-Lymphocyte Ratio, and Disease-Specific Survival in a Retrospective Cohort.

The Journal of dermatology·2026

IL-17 Signaling Inhibitors in Localized Scleroderma: A Single-Center Case Series of Nine Patients.

The Journal of dermatology·2026

Wound, Pressure Ulcer, and Burn Guidelines (2023)-6: Guidelines for the Management of Burns, Third Edition.

The Journal of dermatology·2026

Hypopigmented Mycosis Fungoides With Childhood-Onset and Middle-Aged Onset: Two Case Reports Focusing on the Cutaneous Immune Microenvironment.

The Journal of dermatology·2026

Clinical positioning and future prospects of JAK inhibitors in alopecia areata.

Expert opinion on pharmacotherapy·2026

Circumscribed Morphea Successfully Treated With Excimer Laser: Analysis of Histopathological Changes.

The Journal of dermatology·2026

Three Cases of Merkel Cell Carcinoma Treated With Lutetium-177 Oxodotreotide.

The Journal of dermatology·2026

Local Low-Frequency Vibration Enhances Wound-Healing and Modulates Cellular Senescence in Tissues and Exudates in a Hyperglycemic Rat Model.

The Journal of dermatology·2026

Amenamevir Transfer into Breast Milk in Patients with Herpes Simplex Virus Infection: A Brief Report of a Prospective Multicenter Study.

The Journal of dermatology·2026

From Pustules to Pruritus: A Novel IL36RN Frameshift Variant Reveals a Triple Biologic Paradox and a Th17-To-Th2 Phenotypic Transition.

The Journal of dermatology·2026

Eosinophil-To-Lymphocyte Ratio and Neutrophil-To-Lymphocyte Ratio in Erythroderma: An Exploratory Subtype-Stratified Pilot Study.

The Journal of dermatology·2026

RETRACTION: Comparative Efficacy of Janus Kinase Inhibitors Indicated for Severe Alopecia Areata: A Bayesian Network Meta-Analysis and Matching-Adjusted Indirect Comparison.

The Journal of dermatology·2026

ITPRIPL1: A tumor immune-associated biomarker with prognostic and therapeutic implications in gastrointestinal cancer.

Scientific reports·2026

Differential effects of BCG-Russia and BCG-TICE on trained immunity: Potential implications for bladder cancer immunotherapy.

PloS one·2026

Spatial statistics infer structured immune signatures in primary prostate cancer.

Cancer immunology research·2026

Integrated molecular and immune profiling identifies FOXA1 as a complementary co-target to MUC1 for bispecific immunotherapy in breast cancer.

Functional & integrative genomics·2026

Incidental Thyroid Uptake on 18F-FES PET/CT Revealing Papillary Thyroid Carcinoma.

Clinical nuclear medicine·2026

IL-23 promotes PD-L1 expression and tumor immune evasion via METTL16 pathway.

American journal of cancer research·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us